Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01013831
Other study ID # NCI-2013-00750
Secondary ID NCI-2013-00750RP
Status Terminated
Phase Phase 1
First received November 13, 2009
Last updated February 17, 2015
Start date October 2009
Est. completion date June 2013

Study information

Verified date April 2014
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of erlotinib hydrochloride in preventing cancer in patients with precancerous lesions of the lung. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Description:

PRIMARY OBJECTIVES:

I. To determine the lowest dose of erlotinib (erlotinib hydrochloride) that will decrease the ratio of phosphorylated to total epidermal growth factor receptor (EGFR) (phosphorylated EGFR [pEGFR]/EGFR) by at least 20% in subjects with premalignant lesions of the lung. This will be accomplished by implementing a dose de-escalation trial of erlotinib (i.e., 75, 50, and 25 or 100 mg by mouth daily for a 3-month period), and determining the pEGFR/EGFR ratio in premalignant lesions of the lung epithelium by immunohistochemistry. Changes in the pEGFR/EGFR ratio will be assessed by comparing the pre-treatment (baseline) ratio to that of the post-treatment (3 month) ratio, measured in paraffin embedded biopsy specimens.

SECONDARY OBJECTIVES:

I. To determine the effect of erlotinib on the following biomarkers of potential biological relevance in paraffin embedded lung biopsies, p-v-akt murine thymoma viral oncogene homolog 1 (Akt), p-mitogen-activated protein kinase 1 (Erk), and marker of proliferation Ki-67 (Ki67).

II. To characterize the toxicity profile of erlotinib in this cohort of subjects.

III. To analyze and model erlotinib's pharmacokinetic/pharmacodynamic (PK/PD) profile. Serial blood samples will be drawn at the beginning and at the end of erlotinib treatment, and pharmacokinetic parameters will be determined. The status of EGFR genotype (and that of others genes linked to erlotinib PK/PD) clinical toxicity, and dose will be examined as possible other influential covariates by comparing them to experimentally measured PK profiles, and PD profiles (in particular, the pEGFR/EGFR ratio). The goal of these studies will be to determine the optimal biologic concentration (OBC) of Erlotinib that is associated with the lowest toxicity and highest effect, for a given subject's pharmacogenomic profile.

OUTLINE:

Patients receive erlotinib hydrochloride orally (PO) once daily (QD) for 90 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days.


Recruitment information / eligibility

Status Terminated
Enrollment 60
Est. completion date June 2013
Est. primary completion date February 2012
Accepts healthy volunteers No
Gender Both
Age group 40 Years to 79 Years
Eligibility Inclusion Criteria:

- Diagnosis of a premalignant lung lesion (metaplasia or dysplasia) on autofluorescent bronchoscopy (AFB) within 1 month

- Participants must have a >= 10 pack year lifetime smoking history; current and former smokers only are eligible for this trial

- No contraindications for treatment with erlotinib or additional bronchoscopies

- Absolute neutrophil count (ANC) of >= 1.5 x 10^9/L

- Platelet count of >= 100 x 10^9/L

- Creatinine level of less than 1.5 mg/dL

- Total bilirubin =< 2.0 mg/dl

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN)

- Alkaline phosphatase =< 2.5 x ULN

- Must meet Eastern Cooperative Oncology Group (ECOG) performance status criteria of 0-1

- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) throughout the duration of the study and for 1 month following cessation of study drug; females must begin adequate contraception immediately following screening pregnancy test; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately; if she is pregnant, she will be immediately withdrawn from the study

- Ability to understand and the willingness to sign a written institutional review board (IRB) approved informed consent document

Exclusion Criteria:

- Subjects with life-threatening medical conditions that would preclude the treatment intervention and bronchoscopy, including, but not limited to, unstable pulmonary function, acute cardiac failure, which is unstable despite medication use; uncontrolled hypertension; uncontrolled diabetes mellitus; unstable coronary artery disease; acute or chronic liver disease, ongoing or active infection; or psychiatric illness/social situations that would limit compliance with study requirements

- Participants with evidence of an active cancer or carcinoma in situ, are not eligible

- Participants currently taking medications that induce or inhibit the cytochrome P450, family 3, subfamily A, polypeptide 4-7 (CYP3A4-7) enzymes

- Participants may not be receiving any other investigational agents within 3 months

- Participants taking warfarin

- History of allergic reactions attributed to erlotinib, a known hypersensitivity to erlotinib, or agents with a similar chemical or biological composition to erlotinib

- Women who are pregnant or lactating are excluded from the study because based on the proposed mechanism of tyrosine kinase inhibition of erlotinib; erlotinib should be assumed to cause fetal harm when administered to a pregnant woman; there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with erlotinib

- History of interstitial lung disease (ILD)

Study Design

Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Intervention

Drug:
Erlotinib Hydrochloride
Given PO
Other:
Laboratory Biomarker Analysis
Correlative studies
Pharmacological Study
Correlative studies

Locations

Country Name City State
United States Boston University School of Medicine Boston Massachusetts
United States Roswell Park Cancer Institute Buffalo New York
United States Northwestern University Chicago Illinois
United States University of Chicago Comprehensive Cancer Center Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other PK/PD parameters Up to 90 days No
Other Pharmacogenomic profile Up to 90 days No
Primary Change in the ratio of p-EGFR to total EGFR Baseline up to 90 days No
Secondary Change in the expression of p-Akt Analyzed using an analysis-of-variance (ANOVA) on the change from baseline expression level with a factor for dose (75, 50, 25 or 100). All tests will be two-sided and tested at level alpha=0.05. If the overall comparison is significant, pairwise comparisons will be done using straight Bonferroni adjustments. Baseline up to 90 days No
Secondary Change in the expression of p-Erk Analyzed using an ANOVA on the change from baseline expression level with a factor for dose (75, 50, 25 or 100). All tests will be two-sided and tested at level alpha=0.05. If the overall comparison is significant, pairwise comparisons will be done using straight Bonferroni adjustments. Baseline up to 90 days No
Secondary Change in the expression of Ki67 Analyzed using an ANOVA on the change from baseline expression level with a factor for dose (75, 50, 25 or 100). All tests will be two-sided and tested at level alpha=0.05. If the overall comparison is significant, pairwise comparisons will be done using straight Bonferroni adjustments. Baseline up to 90 days No
Secondary Incidence of toxicities, graded according to Common Toxicity Criteria, version 3.0 Up to 30 days Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05809999 - IBD Neoplasia Surveillance RCT N/A
Completed NCT04153266 - Oral Epithelial Dysplasia Informational Needs Questionnaire
Completed NCT05161013 - A Proof-of-Concept Study Evaluating LINFU™ N/A
Completed NCT04072913 - Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix N/A
Completed NCT04067778 - IBD Neoplasia Surveillance Pilot RCT N/A
Recruiting NCT06281392 - Artificial Intelligence and Dysplasia Detection in Inflammatory Bowel Disease (EIIDISIA Study) N/A
Completed NCT05171634 - Artificial Intelligence and Dysplasia Detection in Ulcerative Colitis (CUDISIA Study) N/A
Recruiting NCT06430372 - Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal Tract Phase 1
Active, not recruiting NCT02790853 - Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders Early Phase 1
Recruiting NCT04867590 - A Study Comparing the Effectiveness of EndoRotor Versus Radiofrequency in Treating Barrett's Esophagus N/A
Completed NCT02075905 - Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management N/A
Completed NCT01140178 - A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx Phase 1
Terminated NCT02481687 - The Value of I-Scan and Confocal Laser Endomicroscopy for the Assessment of Chronic Inflammatory Bowel Disease N/A
Completed NCT01799200 - Hip Pathomorphology in Collegiate Athletes and Controls N/A
Recruiting NCT04054713 - Acetic Acid for the Detection of Esophageal Neoplasms N/A
Completed NCT03268993 - Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer N/A
Active, not recruiting NCT01816438 - A French Non Interventional Multicentric Cohort Study in Patients With Colorectal Dysplasia
Terminated NCT00358111 - Study of LUMA Cervical Imaging System as Adjunct to Colposcopy Phase 4
Active, not recruiting NCT01688908 - Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC) N/A
Completed NCT02100189 - Esophageal Cytology With FISH in Detecting Esophageal Cancer N/A